Table 3

Sample proportions (% (n)) for testing and treatment outcomes and behaviour by treatment arm

Arm 1:
50% RDT subsidy and 100% ACT subsidy
Arm 2:
50% RDT subsidy and 67% ACT subsidy
Arm 3:
No RDT subsidy and 100% ACT subsidy
Arm 4:
No RDT subsidy and 67% ACT subsidy
Total
(n=210)(n=211)(n=213)(n=202)(n=836)
RDT uptake98.6% (207)100.0% (211)96.2% (205)96.5% (195)97.8% (818)
Negative85.0% (176)78.2% (165)75.1% (154)76.4% (149)78.7% (644)
No ACT94.9% (166)93.9% (155)93.5% (144)91.0% (132)93.4% (597)
ACT5.1% (9)6.1% (10)6.5% (10)9.0% (13)6.6% (42)
Missing(1)(0)(0)(4)(5)
Positive15.0% (31)21.8% (46)24.9% (51)23.6% (46)21.3% (174)
No ACT22.6% (7)13.0% (6)7.8% (4)15.2% (7)13.8% (24)
ACT77.4% (24)87.0% (40)92.2% (47)84.8% (39)86.2% (150)
Appropriate ACT use92.2% (190)92.4% (195)93.2% (191)89.5% (171)91.9% (747)
No RDT uptake1.4% (3)0.0% (0)3.8% (8)3.5% (7)2.2% (18)
No ACT100.0% (3)NA50.0% (4)71.4% (5)66.7% (12)
ACT0.0% (0)NA50.0% (4)28.6% (2)33.3% (6)
Targeted ACT use90.9% (190)92.4% (195)89.7% (191)86.4% (171)89.9% (747)
  • Appropriate ACT=(# of participants taking ACT if positive or not taking ACT if negative)/(# of participants who had an RDT test), excluding the missing ACT behaviours.

  • Targeted ACT use=(# of participants taking ACT if positive or not taking ACT if negative)/(# of all participants including those without a test), excluding the missing ACT behaviours.

  • ACT, artemisinin-combination therapy; RDT, rapid diagnostic test.